title: Behavioral economic analysis of drug preference using multiple choice procedure data.
abstract: The multiple choice procedure has been used to evaluate preference for psychoactive drugs, relative to money amounts (price), in human subjects. The present re-analysis shows that MCP data are compatible with behavioral economic analysis of drug choices. Demand curves were constructed from studies with intravenous fentanyl, intramuscular hydromorphone and oral methadone in opioid-dependent individuals; oral d-amphetamine, oral MDMA alone and during fluoxetine treatment, and smoked marijuana alone or following naltrexone pretreatment in recreational drug users. For each participant and dose, the MCP crossover point was converted into unit price (UP) by dividing the money value ($) by the drug dose (mg/70kg). At the crossover value, the dose ceases to function as a reinforcer, so "0" was entered for this and higher UPs to reflect lack of drug choice. At lower UPs, the dose functions as a reinforcer and "1" was entered to reflect drug choice. Data for UP vs. average percent choice were plotted in log-log space to generate demand functions. Rank of order of opioid inelasticity (slope of non-linear regression) was: fentanyl>hydromorphone (continuing heroin users)>methadone>hydromorphone (heroin abstainers). Rank order of psychostimulant inelasticity was d-amphetamine>MDMA>MDMA+fluoxetine. Smoked marijuana was more inelastic with high-dose naltrexone. These findings show this method translates individuals' drug preferences into estimates of population demand, which has the potential to yield insights into pharmacotherapy efficacy, abuse liability assessment, and individual differences in susceptibility to drug abuse.
authors.affiliation: Substance Abuse Research Division, Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI, USA. mgreen@med.wayne.edu
authors.forename: Mark K
authors.initials: MK
authors.lastname: Greenwald
mesh_terms: D002755:Choice Behavior; D004467:Economics; D005283:Fentanyl / Q000191:economics; D005473:Fluoxetine / Q000627:therapeutic use; D006213:Hallucinogens / Q000191:economics; D006801:Humans; D004091:Hydromorphone / Q000008:administration & dosage / Q000191:economics; D007273:Injections, Intramuscular; D008691:Methadone / Q000191:economics / Q000627:therapeutic use; D008960:Models, Psychological; D009042:Motivation; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000191:economics; D009271:Naltrexone / Q000191:economics / Q000627:therapeutic use; D009294:Narcotics / Q000191:economics; D011619:Psychotropic Drugs / Q000191:economics*; D011998:Recreation / Q000191:economics; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D015819:Substance Abuse, Intravenous / Q000191:economics / Q000453:epidemiology; D019966:Substance-Related Disorders / Q000191:economics* / Q000453:epidemiology* / Q000534:rehabilitation
chemical_list: D005283:Fentanyl; D005473:Fluoxetine; D006213:Hallucinogens; D004091:Hydromorphone; D008691:Methadone; D018817:N-Methyl-3,4-methylenedioxyamphetamine; D009271:Naltrexone; D009294:Narcotics; D011619:Psychotropic Drugs; D017367:Selective Serotonin Reuptake Inhibitors